APA (7th ed.) Citation

Janku, F., Kim, T. M., Iyer, G., Spreafico, A., Elez, E., de Jonge, M., . . . Dummer, R. (2024). First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. European journal of cancer, 196, . https://doi.org/10.1016/j.ejca.2023.113458

Chicago Style (17th ed.) Citation

Janku, Filip, et al. "First-in-human Study of Naporafenib (LXH254) with or Without Spartalizumab in Adult Patients with Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations." European Journal of Cancer 196 (2024). https://doi.org/10.1016/j.ejca.2023.113458.

MLA (9th ed.) Citation

Janku, Filip, et al. "First-in-human Study of Naporafenib (LXH254) with or Without Spartalizumab in Adult Patients with Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations." European Journal of Cancer, vol. 196, 2024, https://doi.org/10.1016/j.ejca.2023.113458.